<?xml version="1.0" encoding="UTF-8"?>
<ref id="B60-vaccines-07-00070">
 <label>60.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Fouts</surname>
    <given-names>A.E.</given-names>
   </name>
   <name>
    <surname>Chan</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Stefan</surname>
    <given-names>J.P.</given-names>
   </name>
   <name>
    <surname>Vandler</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Feierbach</surname>
    <given-names>B.</given-names>
   </name>
  </person-group>
  <article-title>Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin</article-title>
  <source>J. Virol.</source>
  <year>2012</year>
  <volume>86</volume>
  <fpage>7444</fpage>
  <lpage>7447</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.00467-12</pub-id>
  <pub-id pub-id-type="pmid">22532696</pub-id>
 </element-citation>
</ref>
